Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma

MLA

Mary E.D. Flowers, et al. “Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.” Biology of Blood and Marrow Transplantation, vol. 24, Nov. 2018, pp. 2211–15. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b2a57567af6b7e7aef8878b1dc47ae28&authtype=sso&custid=ns315887.

APA

Mary E.D. Flowers, Rainer Storb, Brenda M. Sandmaier, Ajay K. Gopal, Oliver W. Press, Camille E. Puronen, Damian J. Green, David G. Maloney, Ryan D. Cassaday, & Philip A. Stevenson. (2018). Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 24, 2211–2215.

Chicago

Mary E.D. Flowers, Rainer Storb, Brenda M. Sandmaier, Ajay K. Gopal, Oliver W. Press, Camille E. Puronen, Damian J. Green, David G. Maloney, Ryan D. Cassaday, and Philip A. Stevenson. 2018. “Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.” Biology of Blood and Marrow Transplantation 24 (November): 2211–15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b2a57567af6b7e7aef8878b1dc47ae28&authtype=sso&custid=ns315887.